



Letter of study termination

Bresso (Milan), 30/07/2021

RE: Clinical study PrefoDIP "Evaluation of the effect exerted by 5-methyltetrahydrofolate (5-MTHF) and folic acid in postmenopausal women" EudraCT Number 2011-005666-37.

Dear Sirs,

We are writing to inform you that the sponsor Zambon SpA has decided to prematurely end the PrefoDIP clinical trial of PREFOLIC (5-methyltetrahydrofolate). The premature end of the study is based on the voluntary, business-related decision of the sponsor.

Nevertheless, Zambon remains committed to evaluating the effects of different forms of folates on cardiovascular risk factors in postmenopausal patients.

If you have any questions or require additional information, please contact Valentina Vaja, email: Valentina.Vaja@ZambonGroup.com.

We are asking for your kind relevant actions.

Kindest regards,

Valentina Vaja
Global Head of Scientific Operations

Zambon S.p.A.



Direzione e amministrazione
Sede legale/Head Office/Registered Office
Via Lillo del Duca 10 - 20091 Bresso (MI) - Italia
Tel. +39 02 665 241 - Fax +39 02 665 01492
CP/PO Box 78 - 20091 Bresso (MI) - Italia

Zambon SpA
Cap. Soc. Euro 5.649.880,00 i.v.
REA Milano n.1814364 C.F. - P.IVA IT 05341830965
Società unipersonale - Direzione e coordinamento:
Zambon Company S.p.A.

